JCM
CCXI

JS Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

JS Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,900
Closed -$269K – 209
2020
Q3 		$269K Buy
+4,900
New +$264K 0.01% 108

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JS Capital Management's CCXI Position: Q4 2020 in Review

JS Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 4,900 shares — an estimated $269K sold.

JS Capital Management first reported a position in CCXI in Q3 2020 and held it in 1 quarter. The position peaked at $269K in Q3 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

  • JS Capital Management reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
  • JS Capital Management sold 4,900 ChemoCentryx, Inc. shares in Q4 2020, an estimated $269K.
  • JS Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2020 and held it in 1 quarter.
  • JS Capital Management's ChemoCentryx, Inc. position peaked at $269K in Q3 2020.
  • 196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on JS Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.